Navigation Links
Signum Biosciences, Inc. Announces Collaborative Agreement with GlaxoSmithKline
Date:11/10/2011

PRINCETON, N.J., Nov. 10, 2011 /PRNewswire/ -- Signum Biosciences, Inc., a privately held biotechnology company, has entered into an agreement with GlaxoSmithKline (China) R&D Company Limited (GSK) to collaborate on Signum's phosphatase screening technology and Phosphoprotein Phosphatase 2A (PP2A).

The agreement provides Signum with research support and milestone payments.  GSK receives the exclusive right of Signum's proprietary phosphatase screening technology for GSK's research and development activities in neurosciences.

GSK and Signum will undertake a broad R&D collaboration to screen and identify PP2A targeted compounds including those bridging the link between PP2A methylation and tau hyperphosphorylation.  Signum's partnership with GSK furthers Signum's position as an innovative biotech company, advancing pioneering drug discovery and leveraging GSK's capabilities in research and development.

Maxwell Stock, President of Signum Biosciences, commented, "GSK is an ideal partner for Signum.  We will develop therapeutics using our phosphatase screening technology in an alliance that utilizes the expertise of both companies.  We are proud to be working in collaboration with a leading pharmaceutical company in innovative research and development.  Collaborations such as these allow partners to share knowledge, expertise and resources and thereby provide a highly effective way of progressing cutting edge research and developing an effective drug."  

About Signum Biosciences, Inc.

Signum, a Princeton, New Jersey- based biotechnology company, dedicated to developing small-molecule therapeutics derived from its Phosphatase platform to modulate signal transduction imbalances.  Through research on protein networks that control biological systems, Signum is developing therapeutic agents for Alzheimer's, Parkinson's and other neurodegenerative diseases.  Signum's technology provides many opportunities for the development of novel consumer products and pharmaceutical candidates.  For further information please visit www.signumbiosciences.com.


'/>"/>
SOURCE Signum Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Signum Biosciences Awarded Two Additional NIH Grants for Development of Topical Therapeutics
2. Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
3. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
4. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
5. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
6. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
7. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
8. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
9. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
11. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 2016 The World Health Organization (WHO) expanded the ... include adolescents aged 13 years, and above. Effective immediately, the ... adult and adolescent males in the 14 priority countries in ... the first male circumcision device to receive WHO Prequalification on ... Horowitz said: " The expanded use of ...
(Date:5/23/2016)... ABU DHABI , UAE, May 23, 2016 ... the importance of Precision Medicine and the role ...     The First International ... under the distinguished patronage and presence of Sheikh ... Development. The conference focused in Precision Medicine, which helps provide ...
(Date:5/23/2016)... -- The global  reprocessed medical devices market ... according to a new study by Grand View Research, ... the lack of centralized support for waste disposal in ... for reprocessed medical devices market. Additionally, the long-term cost-efficiency ... the original device is the high impact rendering driver ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... Backed by decades ... for each job, ensuring the best suited solution to meet regulatory requirements. Their ... at their lab in Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of ...
(Date:5/24/2016)... CA (PRWEB) , ... May 24, 2016 , ... ... everything egg freezing, today announced the official relaunch of its community and education ... their frozen eggs. Eggsurance's mission is to create a safe and welcoming place ...
(Date:5/24/2016)... ... 24, 2016 , ... The Radiosurgery Society (RSS), a non-profit ... recognizing five medical residents and students for their outstanding contributions to research in ... will be presented at the 2016 SRS/SBRT Scientific Meeting taking place June 16-18, ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... 2016 increased by 9.3 million people, or 10% over last year, according to ... people covered under group policies was comparatively stable, with a slight decrease in ...
(Date:5/24/2016)... ... 24, 2016 , ... Bio-Logic Aqua® Research Water Life Science® ... a trainer for Ageless Grace ( http://www.agelessgrace.com ) to discuss healthier lifestyles, especially ... 2016. , Formerly a Northwestern University Literature Professor, Kinst gravitated to her career ...
Breaking Medicine News(10 mins):